Plant Name: Plumbago europaea
Taxonomic Information:
Plant ID: NPO25454
Plant Latin Name: Plumbago europaea
Taxonomy Genus: Plumbago
Taxonomy Family: Plumbaginaceae
Plant External Links:
NCBI TaxonomyDB:
114226
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Turkey; ChinaTraditional Medicine System:
TCMMedicinal Functions:
Acrid; Emetic; Odontalgic; Sialagogue; Vesicant
Geographical Distribution:
Turkey; China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| MAPK1; | |
| NR0B1; | |
| NR3C1; | |
| ALOX15; | |
| KDM4E; | |
| TP53; HIF1A; | |
| EP300; | |
| SLC6A2; SLC6A3; SLCO1B3; SLCO1B1; | |
| MAPT; PAX8; NPC1; RAB9A; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 0 group B | NR0B1 | Nuclear receptor subfamily 0 group B member 1 | P51843 | CHEMBL1795094 |
| Nuclear hormone receptor subfamily 3 group C | NR3C1 | Glucocorticoid receptor | P04150 | CHEMBL2034 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| SLC superfamily of solute carriers | SLC6A3 | Dopamine transporter | Q01959 | CHEMBL238 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | PAX8 | Paired box protein Pax-8 | Q06710 | CHEMBL2362980 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.559E-08 | 5.572E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.802E-07 | 1.608E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.156E-06 | 5.033E-03 | ALOX15, HIF1A, MAPK1, NPC1, SLC6A3, TP53 |
| MF | GO:0005215; transporter activity | GO:0005330; dopamine:sodium symporter activity | 3.712E-06 | 1.283E-02 | SLC6A2, SLC6A3 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 4.124E-06 | 1.283E-02 | MAPT, SLC6A3, TP53 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.238E-06 | 1.299E-02 | CYP2C19, CYP2C9, CYP3A4, NPC1, NR0B1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.226E-06 | 1.299E-02 | HIF1A, MAPT, NR3C1 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.420E-06 | 1.299E-02 | CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.500E-06 | 1.299E-02 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0051179; localization | 1.471E-05 | 1.754E-02 | ALOX15, HIF1A, LMNA, MAPK1, MAPT, NPC1, NR0B1, RAB9A, SLC6A2, SLC6A3, SLCO1B1, SLCO1B3, SMN1, SMN2, TP53 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 5.859E-05 | 3.272E-02 | HIF1A, MAPK1, MAPT |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 8.117E-05 | 3.846E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 9.586E-05 | 4.014E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.560E-08 | 3.149E-06 | CYP2C9, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 4.143E-06 | 2.386E-04 | PAX8, MAPK1, TP53 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.306E-06 | 2.386E-04 | CYP2C9, ALOX15, MAPK1, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.758E-06 | 2.386E-04 | EP300, MAPK1, TP53, HIF1A |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.189E-05 | 7.737E-04 | CYP2C9, ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.989E-05 | 7.737E-04 | PAX8, EP300, MAPK1, HIF1A, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 5.054E-05 | 7.737E-04 | EP300, MAPK1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.287E-05 | 7.737E-04 | MAPK1, TP53, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 5.774E-05 | 7.737E-04 | CYP2C9, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.234E-04 | 1.265E-03 | EP300, MAPK1, TP53 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.290E-05 | 7.737E-04 | SLCO1B1, SLCO1B3, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.902E-04 | 1.800E-03 | EP300, MAPK1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.670E-05 | 1.081E-03 | CYP2C9, CYP3A4, CYP2C19 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 4.690E-04 | 4.120E-03 | LMNA, MAPK1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.301E-04 | 4.347E-03 | EP300, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.376E-03 | 9.590E-03 | MAPK1, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.415E-03 | 9.590E-03 | EP300, MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 1.481E-03 | 9.590E-03 | MAPK1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.228E-04 | 7.094E-03 | MAPK1, TP53 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | NR3C1; |
| NA: NA | Non-infectious rhinitis | NA | NR3C1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | NR3C1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Eczema | L20-L30 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | NR3C1; |
| H60-H95: Diseases of the ear and mastoid process | Otitis externa | H60 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Duchenne muscular dystrophy | G71.0 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | NR3C1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cushing's disease | E24.0 | NR3C1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | NR3C1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Spinal cord injury | S14, S24, S34 | NR3C1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | NR3C1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Skin allergies | T78.4 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | NR3C1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | NR3C1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Xerophthalmia | E50.6-E50.7 | NR3C1; |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | NR3C1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NR3C1; |
| NA: NA | Corticosteroid-responsive inflammation | NA | NR3C1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | NR3C1; |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
